Pharma BD Deal Intelligence

Gilead Sciences, Inc. / Nimbus Apollo, Inc. (Nimbus Therapeutics subsidiary)

2016 · Acquisition/Merger · $1.2B · Complete

Announcement Sentiment

Strongly positive

Gilead acquired Nimbus Apollo Inc. (a wholly-owned subsidiary of Nimbus Therapeutics) and its ACC inhibitor program targeting NASH. Nimbus received $400M upfront with up to $800M in additional development milestones. Lead asset NDI-010976 (later firsocostat) became central to Gilead's NASH combination strategy.

Did it work? Outcome assessment

Strategic verdict

Failed to Achieve

Financial impact

Impaired/Written Down

Pipeline outcome

Assets Stalled

Assessment window: 5yr post-close.

Key facts

Announced Apr 04, 2016
Closed May 17, 2016
Deal value $1.2B
Deal type Acquisition/Merger
Therapeutic area Non-alcoholic steatohepatitis (NASH); hepatocellular carcinoma
Indications Non-alcoholic steatohepatitis (NASH); hepatocellular carcinoma
Key assets NDI-010976 (firsocostat) plus preclinical ACC inhibitors
Mechanism Allosteric Acetyl-CoA Carboxylase (ACC) inhibitor

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals